BioCatalystWatch
EDITWorkspace / EDIT / OverviewCompany library
Editas Medicine, Inc. logo

Editas Medicine, Inc.

Editas Medicine, Inc. (EDIT)

Website

Price
Market cap
Next catalystDosing planned in 2026; New Zealand participation subject to approvalEDIT-401 — Strive · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

EDIT-401

LDLR regulatory region

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

EDIT-401

LDLR regulatory region

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

RP4

PreINDP1P2P3FilingApproved
EDIT-201

CISH × TGFβR2

Partner / License out

CD70

PreINDP2P3FilingApproved

History / paused

HBG1 promoter × HBG2 promoter

PreINDP1P2P3FilingApproved

HBG1 promoter × HBG2 promoter

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

RHO

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

EDIT PR & News

PR & News

EDIT SEC archive